Signs and symptoms of overdosage may be immediate such as anorexia, nausea, vomiting, and diarrhea; or delayed such as myelosuppression, liver dysfunction, and gastroenteritis. The oral LD50 of mercaptopurine was determined to be 480 mg/kg in the mouse and 425 mg/kg in the rat.
An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
Patients with this genotype have reduced metabolism of mercaptopurine resulting in increased toxicity.
Patients with this genotype have reduced metabolism of mercaptopurine resulting in increased toxicity.
Patients with this genotype have reduced metabolism of mercaptopurine resulting in increased toxicity.
| Denosumab | The risk or severity of adverse effects can be increased when Denosumab is combined with Mercaptopurine. |
| Etanercept | The risk or severity of adverse effects can be increased when Etanercept is combined with Mercaptopurine. |
| Peginterferon alfa-2a | The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Mercaptopurine. |
| Interferon alfa-n1 | The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Mercaptopurine. |
| Interferon alfa-n3 | The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Mercaptopurine. |
| Peginterferon alfa-2b | The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Mercaptopurine. |
| Anakinra | The risk or severity of adverse effects can be increased when Anakinra is combined with Mercaptopurine. |
| Interferon gamma-1b | The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Mercaptopurine. |
| Interferon alfa-2a | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Mercaptopurine. |
| Aldesleukin | The risk or severity of adverse effects can be increased when Aldesleukin is combined with Mercaptopurine. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Mercaptopurine. |
| Pegaspargase | The risk or severity of adverse effects can be increased when Pegaspargase is combined with Mercaptopurine. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Mercaptopurine. |
| Interferon beta-1b | The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Mercaptopurine. |
| Interferon alfacon-1 | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Mercaptopurine. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Mercaptopurine. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Mercaptopurine. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Mercaptopurine. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Mercaptopurine. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Mercaptopurine. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Mercaptopurine. |
| Alefacept | The risk or severity of adverse effects can be increased when Alefacept is combined with Mercaptopurine. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Mercaptopurine. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Mercaptopurine. |
| Interferon alfa-2b | The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Mercaptopurine. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Mercaptopurine. |
| Phenylalanine | The risk or severity of adverse effects can be increased when Phenylalanine is combined with Mercaptopurine. |
| Flunisolide | The risk or severity of adverse effects can be increased when Flunisolide is combined with Mercaptopurine. |
| Bortezomib | The risk or severity of adverse effects can be increased when Bortezomib is combined with Mercaptopurine. |
| Cladribine | Mercaptopurine may increase the immunosuppressive activities of Cladribine. |
| Carmustine | The risk or severity of adverse effects can be increased when Carmustine is combined with Mercaptopurine. |
| Amsacrine | The risk or severity of adverse effects can be increased when Amsacrine is combined with Mercaptopurine. |
| Bleomycin | The risk or severity of adverse effects can be increased when Bleomycin is combined with Mercaptopurine. |
| Chlorambucil | The risk or severity of adverse effects can be increased when Chlorambucil is combined with Mercaptopurine. |
| Raltitrexed | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Mercaptopurine. |
| Mitomycin | The risk or severity of adverse effects can be increased when Mitomycin is combined with Mercaptopurine. |
| Bexarotene | The risk or severity of adverse effects can be increased when Bexarotene is combined with Mercaptopurine. |
| Vindesine | The risk or severity of adverse effects can be increased when Vindesine is combined with Mercaptopurine. |
| Floxuridine | The risk or severity of adverse effects can be increased when Floxuridine is combined with Mercaptopurine. |
| Indomethacin | The risk or severity of adverse effects can be increased when Indomethacin is combined with Mercaptopurine. |
| Tioguanine | The risk or severity of adverse effects can be increased when Tioguanine is combined with Mercaptopurine. |
| Vinorelbine | The risk or severity of adverse effects can be increased when Vinorelbine is combined with Mercaptopurine. |
| Dexrazoxane | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Mercaptopurine. |
| Beclomethasone dipropionate | The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Mercaptopurine. |
| Sorafenib | The risk or severity of adverse effects can be increased when Sorafenib is combined with Mercaptopurine. |
| Streptozocin | The risk or severity of adverse effects can be increased when Streptozocin is combined with Mercaptopurine. |
| Trifluridine | The risk or severity of adverse effects can be increased when Trifluridine is combined with Mercaptopurine. |
| Gemcitabine | The risk or severity of adverse effects can be increased when Gemcitabine is combined with Mercaptopurine. |
| Betamethasone | The risk or severity of adverse effects can be increased when Betamethasone is combined with Mercaptopurine. |
| Teniposide | The risk or severity of adverse effects can be increased when Teniposide is combined with Mercaptopurine. |
| Epirubicin | The risk or severity of adverse effects can be increased when Epirubicin is combined with Mercaptopurine. |
| Chloramphenicol | The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Mercaptopurine. |
| Lenalidomide | The risk or severity of adverse effects can be increased when Lenalidomide is combined with Mercaptopurine. |
| Altretamine | The risk or severity of adverse effects can be increased when Altretamine is combined with Mercaptopurine. |
| Zidovudine | The risk or severity of adverse effects can be increased when Zidovudine is combined with Mercaptopurine. |
| Cisplatin | The risk or severity of adverse effects can be increased when Cisplatin is combined with Mercaptopurine. |
| Oxaliplatin | The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Mercaptopurine. |
| Cyclophosphamide | The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Mercaptopurine. |
| Vincristine | The risk or severity of adverse effects can be increased when Vincristine is combined with Mercaptopurine. |
| Fluorouracil | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Mercaptopurine. |
| Pentostatin | The risk or severity of adverse effects can be increased when Pentostatin is combined with Mercaptopurine. |
| Vinblastine | The risk or severity of adverse effects can be increased when Vinblastine is combined with Mercaptopurine. |
| Fluticasone propionate | The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Mercaptopurine. |
| Fluocinolone acetonide | The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Mercaptopurine. |
| Linezolid | The risk or severity of adverse effects can be increased when Linezolid is combined with Mercaptopurine. |
| Imatinib | The risk or severity of adverse effects can be increased when Imatinib is combined with Mercaptopurine. |
| Triamcinolone | The risk or severity of adverse effects can be increased when Triamcinolone is combined with Mercaptopurine. |
| Clofarabine | The risk or severity of adverse effects can be increased when Clofarabine is combined with Mercaptopurine. |
| Prednisone | The risk or severity of adverse effects can be increased when Prednisone is combined with Mercaptopurine. |
| Pemetrexed | Mercaptopurine may decrease the excretion rate of Pemetrexed which could result in a higher serum level. |
| Fludrocortisone | The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Mercaptopurine. |
| Mycophenolate mofetil | The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Mercaptopurine. |
| Daunorubicin | The risk or severity of adverse effects can be increased when Daunorubicin is combined with Mercaptopurine. |
| Irinotecan | The risk or severity of adverse effects can be increased when Irinotecan is combined with Mercaptopurine. |
| Etoposide | The risk or severity of adverse effects can be increased when Etoposide is combined with Mercaptopurine. |
| Sulfasalazine | The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Mercaptopurine. |
| Dacarbazine | The risk or severity of adverse effects can be increased when Dacarbazine is combined with Mercaptopurine. |
| Temozolomide | The risk or severity of adverse effects can be increased when Temozolomide is combined with Mercaptopurine. |
| Penicillamine | The risk or severity of adverse effects can be increased when Penicillamine is combined with Mercaptopurine. |
| Prednisolone | The risk or severity of adverse effects can be increased when Prednisolone is combined with Mercaptopurine. |
| Sirolimus | The risk or severity of adverse effects can be increased when Sirolimus is combined with Mercaptopurine. |
| Mechlorethamine | The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Mercaptopurine. |
| Azacitidine | The risk or severity of adverse effects can be increased when Azacitidine is combined with Mercaptopurine. |
| Carboplatin | The risk or severity of adverse effects can be increased when Carboplatin is combined with Mercaptopurine. |
| Methylprednisolone | The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Mercaptopurine. |
| Dactinomycin | The risk or severity of adverse effects can be increased when Dactinomycin is combined with Mercaptopurine. |
| Cytarabine | The risk or severity of adverse effects can be increased when Cytarabine is combined with Mercaptopurine. |
| Azathioprine | The risk or severity of adverse effects can be increased when Azathioprine is combined with Mercaptopurine. |
| Hydroxyurea | The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Mercaptopurine. |
| Busulfan | The risk or severity of adverse effects can be increased when Busulfan is combined with Mercaptopurine. |
| Mycophenolic acid | The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Mercaptopurine. |
| Topotecan | The risk or severity of adverse effects can be increased when Topotecan is combined with Mercaptopurine. |
| Thalidomide | The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Thalidomide. |
| Melphalan | The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Melphalan. |
| Fludarabine | The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Fludarabine. |
| Flucytosine | The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Flucytosine. |
| Capecitabine | The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Capecitabine. |
| Trilostane | The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Trilostane. |
| Procarbazine | The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Procarbazine. |
| Arsenic trioxide | The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Arsenic trioxide. |